

Moeenzade et al, *J Dent Res Dent Clin Dent Prospects*, 2022, 16(4), 204-220 doi: 10.34172/joddd.2022.034 https://joddd.tbzmed.ac.ir

# **Review Article**



# Dental pulp stem cells for reconstructing bone defects: A systematic review and meta-analysis

Neda Moeenzade<sup>10</sup>, Mohsen Naseri<sup>2</sup>, Fereshteh Osmani<sup>3</sup>, Fariba Emadian Razavi<sup>4</sup><sup>10</sup>

<sup>1</sup>Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran

<sup>2</sup>Cellular and Molecular Research Center, Department of Molecular Medicine, Birjand University of Medical Sciences, Birjand, Iran

<sup>3</sup>Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran

<sup>4</sup>Clinical Research Development Unit, School of Dentistry, Birjand University of Medical Sciences, Birjand, Iran

## **ARTICLE INFO**

Article History:

Received: July 7, 2022 Accepted: December 2, 2022 ePublished: December 30, 2022

#### Keywords:

Bone regeneration, Dental pulp, Mesenchymal stem cells, Tissue engineering, Meta-analysis

#### Abstract

**Background.** Bone reconstruction with appropriate quality and quantity for dental implant replacement in the alveolar ridge is a challenge in dentistry. As dental pulp stem cells (DPSCs) could be a new perspective in bone regeneration in the future, this study investigated the bone regeneration process by DPSCs.

**Methods.** Electronic searches for articles in the PubMed, EMBASE, and Scopus databases were completed until 21 April 2022. The most important inclusion criteria for selecting in vivo studies reporting quantitative data based on new bone volume and new bone area. The quality assessment was performed based on Cochrane's checklist.

**Results.** After the title, abstract, and full-text screening of 762 studies, 23 studies were included. A meta-analysis of 70 studies that reported bone regeneration based on new bone area showed a statistically significant favorable influence on bone tissue regeneration compared to the control groups (P<0.00001, standardized mean difference [SMD] = 2.40, 95% CI: 1.55–3.26; I<sup>2</sup>=83%). Also, the meta-analysis of 14 studies that reported new bone regeneration based on bone volume showed a statistically significant favorable influence on bone tissue regeneration compared to the control groups (P=0.0003, SMD=1.85, 95% CI: 0.85–2.85; I<sup>2</sup>=84%).

**Conclusion.** This systematic review indicated that DPSCs in tissue regeneration therapy significantly affected bone tissue complex regeneration. However, more and less diverse preclinical studies will enable more powerful meta-analyses in the future.

## Introduction

Reconstruction of bone defects is often a clinical challenge, especially in dentistry. Maxillofacial bone deficiencies result from tooth loss, periodontitis, trauma, tumor removal, congenital anomalies, and radiation-related osteonecrosis. Periodontitis and ridge remodeling following tooth loss is the most common cause of the alveolar bone defect. Successful implant placement requires adequate bone quality and quantity to avoid implant failure; therefore, reconstructing the alveolar ridge is a substantial issue for dental implant-supported prostheses.<sup>1-3</sup>

Autogenous bone grafting is the gold standard for bone regeneration. However, mitigating the complications associated with the harvest of autologous bone was the primary impetus for developing bone graft substitutes.<sup>4</sup> Reconstructing bone defects with tissue engineering using dental pulp stem cells or DPSC is one of the most modern rehabilitation methods that can revolutionize future

#### treatments.5

DPSCs can include self-renewal capacity, multilineage differentiation capacity, high proliferation potential, and clonogenic efficacy. These features have made them the most promising mesenchymal stem cells (MSCs) for clinical purposes. However, many issues and challenges must be addressed before using these cells in clinical treatment.<sup>67</sup>

Tissue engineering scaffolds can facilitate the proliferation and differentiation of progenitor cells. Combining osteogenic cells, osteogenic factors, biocompatible scaffolds, and angiogenesis are the elements of bone tissue engineering. Treatment with bone-related factors, gene transfection, and gene overexpression enhances the bone regeneration potential of DPSCs.<sup>5,8</sup>

Due to the limited clinical trials conducted in the field of bone regeneration by DPSCs, they have not yet been effectively used in clinical treatments. Further

<sup>\*</sup>Corresponding author: Fariba Emadian Razavi, Email: emadian\_f@yahoo.com

<sup>© 2022</sup> The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

investigation of the studies conducted in this field will lead to achieving suitable study designs and, ultimately, the progress of therapy using DPSCs. Since the quantitative evaluation of bone regeneration by DPSCs has not been carefully evaluated in the previous systematic reviews, this study aimed to evaluate the potential of DPSCs in clinical and preclinical bone regeneration from a quantitative point of view. For this purpose, this review study analyzed the amount of bone volume and bone area regenerated by DPSCs.

## Methods

## Protocol

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement<sup>9</sup> was the protocol of this systematic review.

## Focus questions

The objective of this study was to review the literature to answer the focused question systematically:

Do DPSCs improve the quantitative results of bone regeneration?

Which samples, scaffold type, final follow-up, and defect type significantly impact bone regeneration?

## Eligibility criteria

The inclusion criteria for the selection were:

*In vivo* studies, bone defect regeneration therapy utilizing DPSCs, studies reporting quantitative data in the form of new bone volume percentage or new bone area percentage, and studies published in the English language.

The exclusion criteria for the selection were:

Studies reporting only qualitative results of bone regeneration

In studies where the results of bone regeneration had been reported quantitatively, the exclusion criteria were these items:

Standard deviations were not apparent, the numbers of samples were not reported, the created bone defects were not filled by scaffolds seeded with DPSCs in the test group, and an acellular scaffold did not fill the created bone defects in the control group.

## Information sources

Electronic searches were completed for articles in MEDLINE (PubMed), EMBASE, and Scopus databases until 21 April 2022. Also, related systematic references were added.

# Search strategy

The search strategy was: "regenerate \*" AND "bone\*" AND ("stem" or "pulp"), AND "cell."

# **Selection process**

The studies were evaluated by two reviewers separately (NM and FO), and the third reviewer (FE) reviewed the differences.

## Data collection process

Two reviewers (NM and FO) collected data from each report independently.

## Data items

The list and definition of outcomes are as follows:

"Author-year" specifies the author and year of publication.

"Sample" specifies the type of animals with bone defects.

"Number" specifies the total number of test and control group samples.

"Site and size of bone defects" specifies the type of the created bone defects and their dimensions or the dimensions of the bur used.

"Final follow-up" specifies the final duration of treatment by week.

"Laboratory method" specifies the laboratory method.

"Scaffold" specifies the scaffold used.

"Regenerated bone area" specifies the study outcome based on bone area percentage. The results of the test and control groups for each study are stated in this column. In the test group, the defect was filled by scaffolds seeded with DPSCs, and in the control group, the defect was supplied with an acellular scaffold.

"Regenerated bone volume" specifies the study outcome based on bone volume percentage. The results of the test and control groups for each study are stated in this column. In the test group, the defect was filled by scaffolds seeded with DPSCs, and in the control group, the defect was supplied by an acellular scaffold.

## Study risk of bias assessment

Cochrane's risk of bias tool was used to assess the risk of bias in the included studies.<sup>10</sup> The criteria used were as follows: random sequence generation (selection bias), allocation concealment (selection bias), blinding of personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias.

The classification of studies based on seven criteria of risk of bias assessment was as follows:

A study had a low risk of bias if it had none of the types of preferences, a study had a moderate risk of bias if it had one of the types of bigotry, and a study had a high risk of bias if it has more than one type of bias.

## Statistical analysis

Review Manager (RevMan, Computer program, Version 5.4, The Cochrane Collaboration, 2020) was used for statistical analysis. Separate meta-analyses were performed according to regenerated bone volume and area. In addition, subgroup analyses were performed according to the sample, defect, follow-up, and scaffold types.

Meta-analyses were performed using the Z test with random effects weighted inverse variance method. The effect size was measured using standardized mean differences (SMDs) and 95% confidence intervals. SMD < 0.2 was considered a 'small' effect size, SMD between 0.2 and 0.8 represented a 'medium' effect size, and SMD > 0.8 was considered a 'large' effect size. The results were considered significant when P < 0.05. The heterogeneity was assessed using the I<sup>2</sup> test. If I<sup>2</sup> was > 75%, it was interpreted as highly heterogeneous.

#### Results

## Study selection

A total of 762 records were identified through database searches. After removing duplicate articles, in vitro articles, review articles, and articles that did not investigate bone tissue regeneration, the full texts of 78 studies were reviewed. The reasons for excluding studies after a full-text assessment were as follows: The quantitative data were not reported  $(n = 27)^{11-37}$ ; the percentage of new bone volume or new bone area was not reported  $(n = 2)^{47,48}$ ; stem cells from human exfoliated deciduous teeth were used as MSCs  $(n = 2)^{49,50}$ ; the created bone defects in the test group were not filled by scaffolds seeded with DPSCs  $(n = 10)^{51-59}$ ; and the created bone defects in the control group were not filled by an acellular staging  $(n = 5)^{.60-64}$ 

Finally, 23 studies were included in the meta-analysis.<sup>65-87</sup> Figure 1 shows the flow chart.

## Study characteristics

The samples used in the studies were rats in 9 studies,<sup>65,67,69,71,74,76,78,79,85</sup> mice in 5 studies,<sup>80,81,83,84,87</sup> rabbits in 4 studies,<sup>72,77,78,82</sup> sheep in 2 studies,<sup>68,70</sup> and pigs in 2 studies,<sup>73,86</sup>

The bone defects were created in the cranium in 15 studies,<sup>65,67,68-72,74,79,80,82-84,86</sup> in the mandible in 2 studies,<sup>67,73</sup> in the alveolar bone in 4 studies,<sup>68,69,78,86</sup> and in the femur in 2 studies.<sup>70,80</sup> Dimensions of defect, Scaffolding used, and final follow-up varied across studies.

The results were in the form of a new bone area in 10 studies  $^{65,68,70,71,73,74,76,78,79,84}$  and new bone volume in 7 studies.  $^{69,75,80,81,83,85,86}$ 

Six studies reported outcomes in both forms.<sup>66,67,72,77,82,87</sup> Table 1 shows the study characteristics.

## **Risk of bias in studies**

In this category, 2, 8, and 13 articles showed a low, medium, and high risk of bias, respectively. Figures 2 and 3 show reviewing authors' judgments about each risk of bias item presented.




Figure 1. Flow diagram for included searches of databases. Abbreviations: MSCs: mesenchymal stem cells; SHEDs: stem cells from human exfoliated deciduous teeth

Table 1. Classification of in vivo studies based on their features

Author, year	Sample	Number	Site and size of bone defects	Final follow-up	Laboratory method	Scaffold	Regenerated bone area	Regenerated bone volume
Vater et al, 2022 <sup>80</sup>	Mice	23	Femur 15.7 mm <sup>3</sup>	6 Weeks	Histology µCT	МСМ		$\begin{array}{c} T \!=\! 29.45 \!\pm\! 19.5\% \\ C \!=\! 28.28 \!\pm\! 12.8\% \end{array}$
Colorado et al, 2022 <sup>65</sup>	Rats	10	Calvarium 5 mm	10 Weeks	Histology Radiology SEM	PLGA/HA	$T = 5.14 \pm 0.13\%$ C = 4.98 ± 0.16%	
Chan et al, 2022 <sup>77</sup>	Rabbits	12	Calvarium 6 mm	8 Weeks	Histology Histomorphometry Immunohistochemistry µCT	НА-ТСР	T=39.78±2.45% C=38.01±2.45%	T=41.32±3.57% C=39.81±3.16%
Maillard et al, 2022 <sup>81</sup>	Mice	10	Calvarium 3.5 × 1 mm²	8 Weeks	Histology Histomorphometry µCT	Hydrogel		T=11.67±2.85% C=4.84±2.33%
Zhu et al <i>,</i> 2021 <sup>87</sup>	Mice	18	Calvarium 2 mm	8 Weeks	Histology Radiology µCT	Collagen	T=32.51±2.46% C=24.64±2.03%	T=55.86±3.31% C=47.56±2.33%
Shiu et al, 2021 <sup>82</sup>	Rabbits	8	Calvarium 6 mm	8 Weeks	Histology Histomorphometry µCT	MBCP (HA and tricalcium phosphate)	$T = 39.8 \pm 5.7\%$ C = 38.3 ± 6.0%	T=41.0±1.4% C=38.4±1.3%
Shiu et al, 2021 <sup>82</sup>	Rabbits	8	Calvarium 6 mm	8 Weeks	Histology Histomorphometry µCT	Bio-Oss	T=42.1±2.7% C=41.3±3.5%	T=41.2±3.4% C=39.0±5.1%
Park et al, 2020 <sup>83</sup>	Mice	8	Calvarium 4 mm	8 Weeks	Histology Immunohistochemistry µCT	Dense collagen (S53P4)		$T = 3.62 \pm 1.94\%$ C = 6.47 ± 4.08%
in et al, 201967	Rats	10	Mandible 2 × 1 mm <sup>2</sup>	6 Weeks	Histology µCT	Hydrogel	$T = 6.15 \pm 0.55\%$ C = 1.30 ± 0.29%	$T = 26.03 \pm 3.53\%$ C = 8.95 ± 3.25%
Çolpak et al, 2019 <sup>68</sup>	Sheep	32	Alveolar bone 3.7 × 10 mm <sup>2</sup>	6 Weeks	Histology Histomorphometry	Granular deproteinized bovine bone with 10% porcine collagen	T=29±1.07% C=18.45±0.33%	
Lin et al <i>,</i> 2019 <sup>69</sup>	Rats	20	Alveolar bone $2 \times 1.5 \times 0.5$ mm <sup>3</sup>	2 Weeks	Histology µCT	Matrigel		$T = 47.61 \pm 7.08\%$ C = 30.08 ± 2.13%
Campos et al, 2019 <sup>70</sup>	Ovine	12	Femur 5 mm	17 Weeks	Histology Histomorphometry Radiology	Bonelike® plus Tisseel Lyo®	$T = 77.5 \pm 3.2\%$ C = 67.9 ± 3.9%	
Lee YC et al, 2019 <sup>66</sup>	Rabbits	12	Calvarium 6 mm	6 Weeks	Histology Histomorphometry Immunohistochemistry µCT	Bio Oss	T=33.5±9.3% C=25.6±9.7%	$T = 48.3 \pm 3.0\%$ $C = 43.5 \pm 0.9\%$
Yuan et al, 2018 <sup>71</sup>	Rats	20	Calvarium 5 mm	12 Weeks	Histology Histomorphometry Immunohistochemistry µCT	Bio-Oss	T=34.69±4.68% C=24.69±2.44%	
Collignon et al, 2018 <sup>84</sup>	Mice	12	Calvarium 3.5 mm	12 Weeks	Histology Histomorphometry µCT	Collagen	$T = 65.01 \pm 11.38\%$ C = 35.25 ± 18.47%	
Wongsupa et al, 2017 <sup>72</sup>	Rabbits	6	Calvarium 11 mm	8 Weeks	Histology Histomorphometry µCT Clinical	PCL/BCP	T=11.36±3.56% C=6.68±1.38%	T=25.33±0.61% C=13.28±2.46%
Chamieh et al, 2016 <sup>85</sup>	Rats	15	Calvarium 5 mm	5 Weeks	Histology Histomorphometry µCT	Collagen		$T = 9.86 \pm 1.92\%$ C = 3.07 ± 0.52%
Kuo et al, 2015 <sup>73</sup>	Pigs	8	Mandible 6 mm	8 Weeks	Histology Histomorphometry	CSD	$T = 69.7 \pm 4.9\%$ $C = 33.9 \pm 9.9\%$	
Cao et al, 2015 <sup>86</sup>	Pigs	8	Alveolar bone 5×7×3 mm³	12 Weeks	Histology Histomorphometry Radiology Clinical	НА-ТСР		T=56±3.6% C=0.47±2.19%
Petridis et al, 2015 <sup>74</sup>	Rats	30	Calvarium 5 mm	8 Weeks	Histology Histomorphometry	Hydrogel	$T=32.78\pm9.24\%$ $C=24.40\pm8.29\%$	

Table 1. Continu	ed							
Author, year	Sample	Number	Site and size of bone defects	Final follow-up	Laboratory method	Scaffold	Regenerated bone area	Regenerated bone volume
Annibali et al, 2014 <sup>75</sup>	Mice	10	Calvarium 4×1 mm²	8 Weeks	Histology Histomorphometry	Granular deproteinized bovine bone with 10% porcine collagen		T=17.67±20.17% C=16.21±9.74%
Maraldi et al, 2013 <sup>76</sup>	Rats	20	Calvarium 5×8×1.5 mm³	4 Weeks	Histology Histomorphometry Immunohistochemistry Radiology	Collagen	$T = 56.80 \pm 4.34\%$ C = 43.58 ± 7.15%	
Pisciotta et al, 2012 <sup>79</sup>	Rats	10	Calvarium 5×8×1.5 mm³	6 Weeks	Histology Histomorphometry Immunohistochemistry	Collagen	$T = 69.03 \pm 7.87\%$ C = 39.21 ± 4.36%	
Liu et al, 2011 <sup>78</sup>	Rabbits	12	Alveolar bone $10 \times 4 \times 3 \text{ mm}^3$	12 Weeks	Histology Histomorphometry Radiology	nHAC/PLA	T=35.95±2.53% C=22.86±0.55%	

T: test group; C: control group; µCT: X-ray micro-computed tomography; SEM, Scanning electron microscopy; MCM, Mineralized collagen matrix; HA-TCP, Hydroxyapatite /Tricalcium phosphate; HA, hydroxyapatite; PLGA, Polylactide-co-glycolide; CSD, Calcium sulfate dehydrate; PCL/BCP, polycaprolactone/βtricalcium phosphate; HA, Hydroxyapatite; TCP, Tricalcium phosphate; nHAC, Nanohydroxyapatite/ collagen; PLA, poly(L-lactide.




Figure 2. Risk of bias graph: reviewing authors' judgments about each risk of bias item presented as percentages across all included studies

#### Analysis based on new bone area percentage

Seventeen studies reported results based on bone area percentage.<sup>65,66,67,69,71,74–82,84–86</sup> Study results were highly heterogeneous. Bone formation was significantly enhanced in the test groups compared to the control groups (P<0.00001, SMD=2.40, 95% CI: 1.55–3.26; participants = 289; studies = 17;  $I^2$  = 83%) (Figures 4 and 5).

Subgroup analyses showed a statistically significant difference in bone regeneration with different scaffold and defect types. The granular deproteinized bovine bone group enhanced bone regeneration the most (SMD = 12.99 [95% CI: 9.52-16.46]). However, only one study formed this subgroup, and thus this result has low statistical power (Figure 6). The alveolar bone defect subgroup had the biggest and significantly different effect size compared to other defect types (Figure 7). The SMDs in the alveolar and mandibular bone defect subgroup were 9.73 ([95% CI: 3.65-15.89], studies = 2) and 6.46 ([95% CI: 0.69-12.23], studies = 2), respectively, higher than that in the calvarium bone defect subgroup (SMD = 1.39 [95% CI: 0.84-1.95], studies = 12) (Figure 7).

There were no significant differences in final followup and sample types. The most positive impact on bone regeneration occurred in groups where the final followup was six weeks, and the sheep were used as samples (Figures 8 and 9). The outcome of sample types subgroup analysis without considering the subgroups including less than two studies was as follows: The biggest SMD occurred in the rat subgroup (SMD=2.19 [95% CI: 1.05-3.33], studies=6), and the smallest SMD occurred in the rabbit subgroup (SMD=0.97 [95% CI: 0.10-1.84], studies=5) (Figure 6).

# Analysis based on new bone volume percentage

Fourteen studies reported results based on new bone volume percentage.<sup>66,67,68-70,72-75,77,80,83,87</sup> Study results were highly heterogeneous. Bone formation was significantly enhanced in the test groups compared to the control groups (P < 00001, SMD=1.85, 95% CI: 0.85-2.85; participants=205; studies=14; I<sup>2</sup>=84%) (Figures 10 and 11). All the studies showed a net positive effect of DPSCs therapy on bone treatment outcomes. However, two study subgroups<sup>77,83</sup> reported a negative effect compared to the control groups.

Subgroup analyses showed a significant difference in bone regeneration with all the subgroups. However, all




Figure 3. Risk of bias summary: reviewing authors' judgments about each risk of bias item for each included study

the subgroups had only one to two studies, indicating low statistical power. In addition, subgroup analyses showed high heterogeneity (Figures 12, 13, 14, and 15).

Subgroup analyses showed that the most positive impact on bone regeneration occurred in groups where bone defects were created in the alveolar bone, and the pigs were used as samples (Figures 12 and 13). More precisely, the outcomes of subgroup analyses without considering subgroups including less than two studies were as follows: The SMD in the alveolar bone defect subgroup (SMD = 8.48 [95% CI: -4.03-20.96], studies = 2) was higher than that in the calvarium bone defect subgroup (SMD = 1.58 [95% CI: 0.47-2.69], studies = 10) (Figure 13). In the sample type subgroups, the SMDs in the rat, rabbit, and mice subgroups were 4.01 ([95% CI: 2.99-5.03], studies = 3), 1.15 ([95% CI: -0.16-2.45], studies = 5), and 0.94 ([95% CI: -0.36-2.24], studies = 5), respectively (Figure 12).

The most significant positive impact on bone regeneration occurred in groups where the final follow-up was 12 weeks, and hydroxyapatite/tricalcium phosphate (HA-TCP) was used as a scaffold (Figures 14 and 15).

#### **Reporting biases**

There was a possibility of bias due to the small number of studies. Also, the funnel plots of the new bone area and new bone volume indicated an asymmetrical shape. The asymmetrical shape might have been caused by publication bias, study heterogeneity, and methodological anomaly (Figures 5 and 11).

# Discussion

Bone tissue engineering by DPSCs has been the subject of many studies as a method that could have a promising future in alveolar ridge reconstruction. However, despite many advances in this field, the high heterogeneity of studies and the few studies with complete statistical data make high-power statistical analysis impossible and the clinical application and effectiveness of stem cell utilization unclear.

This meta-analysis evaluated the impact of tissue engineering by DPSCs on bone regeneration based on the new bone volume and new bone area formation. Two previous systematic reviews<sup>6,88</sup> mentioned a positive impact of tissue engineering by DPSCs on bone regeneration based on qualitative data. The present study is the first to evaluate the effect of tissue engineering by DPSCs on bone regeneration based on quantitative data.

According to this review, DPSCs and scaffold complexes significantly increase bone regeneration. Clinical diversity and high methodological heterogeneity should be considered in the interpretation of the metaanalysis. Analyses were performed in the subgroups of sample type, scaffold type, final follow-up and defect types. Although heterogeneity decreased in the majority of subgroup analyses, a few studies in subgroups caused the low statistical power of meta-analysis. Nonetheless,

		Test		C	Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Cjolpaket 2019	29	1.07	16	18.45	0.33	16	3.5%	12.99 [9.52, 16.46]	>
Campos 2018	77.5	3.2	36	67.9	3.9	12	7.5%	2.79 [1.92, 3.67]	-
Chan 2022	39.78	2.45	6	38.01	2.45	6	7.0%	0.67 [-0.51, 1.84]	
Collignon 2018	60.01	11.38	6	35.25	18.97	6	6.8%	1.46 [0.12, 2.80]	
Colorado 2022	5.14	0.13	5	4.98	0.16	5	6.7%	0.99 [-0.37, 2.35]	+
Jin 2019	6.15	0.55	5	1.3	0.29	5	1.7%	9.96 [4.22, 15.71]	
Kuo 2015	69.7	4.9	4	33.9	9.9	4	4.0%	3.99 [0.91, 7.06]	
Lee YC 2019	33.5	9.3	12	25.6	9.7	12	7.5%	0.80 [-0.04, 1.64]	
Liu 2011	35.92	2.53	6	22.86	0.55	6	3.5%	6.58 [3.18, 9.99]	
Maraldi 2013	56.8	4.34	10	43.58	7.15	10	7.1%	2.14 [0.99, 3.29]	
Petrides 2015	32.78	9.24	15	24.4	8.3	16	7.7%	0.93 [0.18, 1.68]	+
Pisciotta 2012	69.03	7.87	6	39.21	4.36	4	4.7%	3.98 [1.41, 6.55]	
Shiu1,2021	39.8	5.7	4	38.3	6	4	6.7%	0.22 [-1.17, 1.62]	+
Shiu 2,2021	42.1	2.7	4	41.3	3.5	4	6.7%	0.22 [-1.17, 1.62]	+
Wongsupa 2017	11.36	3.56	3	6.68	1.38	3	5.5%	1.39 [-0.70, 3.47]	+
Yuan 2018	34.69	4.68	10	24.69	2.44	10	6.9%	2.57 [1.32, 3.81]	
Zhu 2021	32.51	2.48	9	24.64	2.03	9	6.4%	3.31 [1.78, 4.84]	
Total (95% CI)			157			132	100.0%	2.40 [1.55, 3.26]	•
Heterogeneity: Tau <sup>2</sup> =	= 2.33; C	hi² = 95.	.59, df=	= 16 (P ·	< 0.000	01); I <sup>z</sup> =	83%	-	
Test for overall effect:	Z = 5.52	? (P ≤ 0.)	00001)						
<b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> =	= 2.33; C	hi² = 95	<b>157</b> .59, df=	= 16 (P ·		132	100.0%		-10 -5 0 5 10 Control Test

Figure 4. Forest plot for new bone area measures




Figure 5. Funnel plot for new bone area measures

the use of DPSCs and scaffold caused a significant increase in the reconstruction of bone defects.

In addition, it is necessary to pay attention to this point that this meta-analysis has not reviewed the impact of other factors, such as growth factors, on bone regeneration. Bone-related factors, gene transfection, and gene overexpression enhance the bone regeneration potential of DPSCs.<sup>5,8</sup> However, meta-analysis was impossible due to the high heterogeneity of methodology in the studies examining these factors' impact on bone tissue engineering. Therefore, we can expect a more significant amount of bone regeneration by DPSCs with the application of growth factors, gene transfection, and gene overexpression.

Using growth factors such as tetrahydroxystilbene glucoside,<sup>69</sup> rhBMP-2,<sup>78</sup> and osteogenic culture medium<sup>48</sup> increased bone regeneration. In addition, overexpression of SIRT1, Runx2, EphrinB2, and DPSCs derived from PN3 Wnt1-CRE-Rosa<sup>Tomato</sup> mouse molar in separate studies<sup>51-53</sup> showed a significant increase in bone regeneration.

Compared to other stem cells, studies comparing the

ability of DPSCs to bone marrow MSCs did not show a significant difference in bone regeneration.<sup>47,50,66,89</sup> However, evaluation of the osteogenic potential of adipose tissue-derived stem cells<sup>67</sup> and amniotic fluid stem cells<sup>76</sup> showed a significant increase in bone regeneration compared to DPSCs.

Overall, using DPSCs with appropriate scaffold, growth factor, and gene therapy will result in the maximum bone regeneration percentage. Finally, as mentioned in previous systematic reviews, bone tissue engineering can be expected to result in a favorable clinical outcome.<sup>6,88</sup>

Few clinical studies examined bone reconstruction in Mansfield.<sup>38-40,43,90,91</sup> Most of these studies have reported new bone regeneration based on probing depth and clinical attachment loss. Future clinical trials should also evaluate the extent of bone regeneration in other ways, such as micro-computed tomography.

Future research should concentrate on humans or samples closer to humans, such as dogs and sheep, than on mice and rats. The results should be in the form of statistical data such as bone volume, trabecular number, bone mineral density, and mineral content.

The new bone formation could include maxillary or mandibular bone defects rather than cranium or subcutaneous ones. Future research should compare the effect of different growth factors, scaffolds, and gene overexpression on bone regeneration.

#### Conclusion

Bone tissue engineering by DPSC is one of the promising ways for bone regeneration in the future. This study was designed in response to the question of whether the current clinical studies quantitatively indicate the ability of DPSC to regenerate bone properly. In this review article, the meta-analysis conducted on the results of the studies showed a significant increase in the amount

Study or Subgroup	Mean	Test SD	Total	C Mean	ontrol SD	Total	S Weight	td. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% Cl
5.1.1 Collagen								,, ,, ,,	,
Collignon 2018		11.38		35.25		6	6.8%	1.46 [0.12, 2.80]	
Maraldi 2013 Pisciotta 2012	56.8 69.03	4.34 7.87	10	43.58 39.21	7.15 4.36	10	7.1% 4.7%	2.14 [0.99, 3.29]	
Zhu 2021	69.03 32.51	2.48	6 9	24.64	2.03	4 9	4.7% 6.4%	3.98 [1.41, 6.55] 3.31 [1.78, 4.84]	
Subtotal (95% CI)		2	31	2	2.00	29	25.0%	2.45 [1.48, 3.41]	◆
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	•			•	.18); I² :	= 38%			
5.1.2 Hydrogel									
Jin 2019	6.15	0.55	5	1.3	0.29	5	1.7%	9.96 [4.22, 15.71]	
Petrides 2015	32.78	9.24	15 20	24.4	8.3	16 <b>21</b>	7.7% <b>9.4%</b>	0.93 [0.18, 1.68]	+
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:			.34, df:	= 1 (P =	0.002);			4.98 [-3.82, 13.78]	
5.1.3 Polycaprolactor	ne /ß-trie	calcium	phose	ohate (P	CL/BCF	2)			
Wongsupa 2017	11.36	3.56	3	6.68	1.38	<b>'</b> 3	5.5%	1.39 [-0.70, 3.47]	
Subtotal (95% CI)			3			3	5.5%	1.39 [-0.70, 3.47]	◆
Heterogeneity: Not ap Test for overall effect:			19)						
5.1.4 Bonelike® plus	Tisseel	Lyo®							
Campos 2018	77.5	3.2	36	67.9	3.9	12	7.5%	2.79 [1.92, 3.67]	<b>±</b>
Subtotal (95% CI)	nlianhla		36			12	7.5%	2.79 [1.92, 3.67]	•
Heterogeneity: Not ap Test for overall effect:	•		00001)	I					
5.1.5 Nanohydroxyap	atite/ co	ollagen/	poly(L-	lactide)	( nHAC	/PLA)			
Liu 2011 Subtotal (95% CI)	35.92	2.53	6 6	22.86	0.55	6 6	3.5% <b>3.5%</b>	6.58 [3.18, 9.99] 6 58 [3 18, 9 99]	
Heterogeneity: Not ap	nlicable		0			0	3.370	6.58 [3.18, 9.99]	
Test for overall effect:	-		0002)						
5.1.6 Calcium sulfate	-								
Kuo 2015 Subtotal (95% Cl)	69.7	4.9	4	33.9	9.9	4	4.0% <b>4.0%</b>	3.99 [0.91, 7.06] 3.99 [0.91, 7.06]	•
Heterogeneity: Not ap Test for overall effect:								0.00 [0.01, 1.00]	
5.1.7 Granular deprot	teinized	bovine	bone v	vith 10%		ie colla	gen( GDPE	3)	
Cjolpaket 2019	29	1.07		18.45	0.33	16	3.5%	12.99 [9.52, 16.46]	
Subtotal (95% CI)			16			16	3.5%	12.99 [9.52, 16.46]	•
Heterogeneity: Not ap Test for overall effect:			00001)	I					
5.1.8 Bio Oss									
Lee YC 2019	33.5	9.3	12	25.6	9.7	12	7.5%	0.80 [-0.04, 1.64]	-
Shiu 2,2021 Yuan 2018	42.1	2.7	4	41.3	3.5	4	6.7% c.ov	0.22 [-1.17, 1.62]	
Subtotal (95% CI)	34.69	4.68	26	24.69	2.44	10 <b>26</b>	6.9% <b>21.2%</b>	2.57 [1.32, 3.81] 1.19 [-0.07, 2.46]	•
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:				2 (P = 0	.03); I² :	= 73%			
5.1.9 Hydroxyapatite	/Tricalc	ium pho	osphat	e(HA-TC	(P)				
Chan 2022	39.78	2.45	-	38.01	2.45	6	7.0%	0.67 [-0.51, 1.84]	<del> _</del>
Subtotal (95% CI) Heterogeneity: Not ap	•		6			6	7.0%	0.67 [-0.51, 1.84]	•
Test for overall effect:	Z = 1.11	(P = 0	21)						
5.1.10 MBCP( Hydrox								0.001117	l
Shiu1,2021 Subtotal (95% CI)	39.8	5.7	4	38.3	6	4	6.7% <b>6.7%</b>	0.22 [-1.17, 1.62] 0.22 [-1.17, 1.62]	<b>→</b>
Heterogeneity: Not ap Test for overall effect:	-					,		[,]	Ţ
5.1.11 Polylactide-co	-alvcolia	de/ hvdr	oxyan	atite (PI	GA/HA	)			
Colorado 2022	5.14	0.13	5	4.98	0.16	5	6.7%	0.99 [-0.37, 2.35]	+ <u>+</u> -
Subtotal (95% CI)			5		-	5	6.7%	0.99 [-0.37, 2.35]	◆
Heterogeneity: Not ap Test for overall effect:			15)						
Total (95% CI)			157			132	100.0%	2.40 [1.55, 3.26]	◆
Heterogeneity: Tau <sup>2</sup> =	2.33; C	hi² = 95.		= 16 (P ·	< 0.000				-20 -10 0 10 20
Test for overall effect:	Z = 5.52	? (P ≤ 0.)	00001)	-					-20 -10 0 10 20 Control Test
Test for subgroup diff	erences	: Chi <sup>z</sup> =	66.70,	df=10	(P < 0.0	)0001),	I <sup>2</sup> = 85.0%		

Figure 6. Forest plot for new bone area measures stratified by scaffold type

		Test			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup 3.1.1 Mandible	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
			-			-			
Jin 2019	6.15	0.55	5	1.3	0.29	5	1.7%	9.96 [4.22, 15.71]	
Kuo 2015	69.7	4.9	4	33.9	9.9	4	4.0% 5.7%	3.99 [0.91, 7.06] 6.46 [0.69, 12.23]	
Subtotal (95% CI)	40.05.	0.52 0		4.00	0.071.17	-		0.40 [0.09, 12.25]	
Heterogeneity: Tau <sup>2</sup> = Test for overall effect				= 1 (P =	0.07); 1-	= 69%			
rest for overall effect	L Z = Z.18	(P = 0.	03)						
3.1.2 Alveolar bone									
Cjolpaket 2019	29	1.07	16	18.54	0.33	16	3.5%	12.88 [9.44, 16.32]	
Liu 2011	35.92	2.53	6	22.86	0.55	6	3.5%	6.58 [3.18, 9.99]	
Subtotal (95% CI)			22			22	7.0%	9.73 [3.56, 15.89]	
Heterogeneity: Tau <sup>2</sup> :	= 16.75; (	Chi <sup>2</sup> = 6	.49. df:	= 1 (P =	0.01); P	= 85%			
Test for overall effect	t: Z = 3.09	) (P = 0.	002)		~				
3.1.3 Calvarium									
Chan 2022	39.78	2.45	6	38.01	2.45	6	7.0%	0.67 [-0.51, 1.84]	
Collignon 2018		11.38	6			6	6.8%	1.46 [0.12, 2.80]	
Colorado 2022	5.14	0.13	5	4.98	0.16	5	6.7%	0.99 [-0.37, 2.35]	-
Lee YC 2019	33.5	9.3	12	25.6	9.7	12	7.5%	0.80 [-0.04, 1.64]	-
Maraldi 2013	56.8	4.34	10		7.15	10	7.1%	2.14 [0.99, 3.29]	-
Petrides 2015	32.78	9.24	15	24.4	8.3	16	7.7%	0.93 [0.18, 1.68]	+
Pisciotta 2012	69.03	7.87	6	39.21	4.36	4	4.7%	3.98 [1.41, 6.55]	
Shiu1,2021	39.8	5.7	4	38.3	6	4	6.7%	0.22 [-1.17, 1.62]	+
Shiu 2,2021	42.1	2.7	4	41.3	3.5	4	6.7%	0.22 [-1.17, 1.62]	+
Wongsupa 2017	11.36	3.56	3	6.68	1.38	3	5.5%	1.39 [-0.70, 3.47]	+
Yuan 2018	34.69	4.68	10	24.69	2.44	10	6.9%	2.57 [1.32, 3.81]	-
Zhu 2021	32.51	2.48	9	24.64	2.03	9	6.4%	3.31 [1.78, 4.84]	
Subtotal (95% CI)			90			89	79.8%	1.39 [0.84, 1.95]	•
Heterogeneity: Tau <sup>2</sup> :	= 0.50; C	hi <b>≊</b> = 24	.99, df:	= 11 (P :	= 0.009)	; I² = 5I	3%		
Test for overall effect	t: Z = 4.91	(P < 0.	00001)	I					
3.1.4 Femor									
Campos 2018	77.5	3.2	36	67.9	3.9	12	7.5%	2.79 [1.92, 3.67]	+
Subtotal (95% CI)			36			12	7.5%	2.79 [1.92, 3.67]	▲
Heterogeneity: Not a	pplicable								
Test for overall effect	t: Z = 6.25	i (P ≤ 0.	00001)						
Total (95% CI)			157			132	100.0%	2.40 [1.55, 3.26]	•
Heterogeneity: Tau <sup>2</sup> :	= 2.331 C	hi² = 95	46 df:	= 16 (P ·	< 0 000				+ + + +
Test for overall effect					5.0000	// - =			-20 -10 0 10 20
Test for subaroup dif					P = 0.00	1). <b> </b> ² =	81.0%		Control Test
					0.00				

Figure 7. Forest plot for new bone area measures stratified by defect type

		Test			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.1.1 Rats									
Colorado 2022	5.14	0.13	5	4.98	0.16	5	6.7%	0.99 [-0.37, 2.35]	+
Jin 2019	6.15	0.55	5	1.3	0.29	5	1.7%	9.96 [4.22, 15.71]	
vlaraldi 2013	56.8	4.34	10	43.58	7.15	10	7.1%	2.14 [0.99, 3.29]	-
Petrides 2015	32.78	9.24	15	24.4	8.3	16	7.6%	0.93 [0.18, 1.68]	-
Pisciotta 2012	69.03	7.87	6	39.21	4.36	4	4.6%	3.98 [1.41, 6.55]	
/uan 2018 Subtotal (95% CI)	34.69	4.68	10 <b>51</b>	24.69	2.44	10 50	6.9% <b>34.6%</b>	2.57 [1.32, 3.81] <b>2.19 [1.05, 3.33</b> ]	
Heterogeneity: Tau² : Fest for overall effect				= 5 (P =	0.002);	l² = 739	%		
2.1.2 Rabbits									
Chan 2022	39.78	2.45	6	38.01	2.45	6	7.0%	0.67 [-0.51, 1.84]	+-
lee YC 2019	33.5	9.3	12	25.6	9.7	12	7.5%	0.80 [-0.04, 1.64]	+
_iu 2011	32.95	2.53	6	22.86	0.55	6	4.4%	5.09 [2.36, 7.82]	<del></del>
3hiu1,2021	39.8	5.7	4	38.3	6	4	6.6%	0.22 [-1.17, 1.62]	+
Shiu 2,2021	42.1	2.7	4	41.3	3.5	4	6.6%	0.22 [-1.17, 1.62]	+
Vongsupa 2017 Subtotal (95% CI)	11.36	3.56	3 35	6.68	1.38	3 35	5.4% <b>37.6%</b>	1.39 [-0.70, 3.47] <b>0.97 [0.10, 1.84]</b>	•
Heterogeneity: Tau <sup>2</sup> :	= 0.60; CI	ni² = 11	.15. df=	= 5 (P =	0.05); l <sup>a</sup>	= 55%			
Fest for overall effect	: Z = 2.18	(P = 0.	03)						
2.1.3 Mice									
Collignon 2018	60.01			35.25		6	6.7%	1.46 [0.12, 2.80]	
Zhu 2021 Subtotal (95% CI)	32.51	2.48	9 15	24.64	2.03	9 15	6.4% 13.1%	3.31 [1.78, 4.84] <b>2.34 [0.54, 4.15]</b>	→
Heterogeneity: Tau² : Fest for overall effect				1 (P = 0	1.08); <b> ²</b> =	= 68%			
2.1.4 Sheep									
Cjolpaket 2019	29	1.07	16	18.45	0.33	16	3.4%	12.99 [9.52, 16.46]	
Campos 2018	77.5	3.2	36	67.9	3.9	12	7.5%	2.79 [1.92, 3.67]	+
ubtotal (95% CI)			52			28	10.9%	7.75 [-2.24, 17.73]	
leterogeneity: Tau² : est for overall effect				′= 1 (P ·	< 0.0001	01); I²=	97%		
2.1.5 Pigs									
<uo 2015<br="">Subtotal (95% CI)</uo>	69.7	4.9	4 4	33.9	9.9	4 4	3.9% <b>3.9%</b>	3.99 [0.91, 7.06] <b>3.99 [0.91, 7.06]</b>	•
leterogeneity: Not a 'est for overall effect			01)						
Fotal (95% CI)			157			132	100.0%	2.37 [1.53, 3.21]	•
Heterogeneity: Tau <sup>2</sup> :	= 2.26; Cl	ni² = 93	.62, df=	= 16 (P ·	< 0.0001	01); <b>I</b> ² =	83%		-20 -10 0 10 2
Fest for overall effect									

Figure 8. Forest plot for new bone area measures stratified by animal type

Study or Subgroup	Mean	Test SD	Total	( Mean	Control SD	Total	Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
4.1.1 4 weeks									
Maraldi 2013 Subtotal (95% CI)	56.8	4.34	10 <b>10</b>	43.58	7.15	10 <b>10</b>	7.4% <b>7.4%</b>	2.14 [0.99, 3.29] <b>2.14 [0.99, 3.29]</b>	 ◆
Heterogeneity: Not a	pplicable								
Test for overall effect	: Z = 3.66	(P = 0.1	0003)						
4.1.2 6 weeks									
C jolpaket 2019	29	1.07		18.45	0.33	16	3.6%	12.99 [9.52, 16.46]	
Jin 2019	6.15	0.55	5	1.3	0.29	5	1.8%	9.96 [4.22, 15.71]	
Lee YC 2019 Subtotal (95% CI)	33.5	9.3	12 33	25.6	9.7	12 33	7.9% <b>13.4%</b>	0.80 [-0.04, 1.64] 7.75 [-1.44, 16.95]	
Heterogeneity: Tau <sup>2</sup> : Test for overall effect				f= 2 (P	< 0.000	01); I² =	96%		
4.1.3 8 weeks									
Chan 2022	39.78	2.45	6	38.01	2.45	6	7.4%	0.67 [-0.51, 1.84]	
Kuo 2015	69.7	4.9	4	33.9	9.9	4	4.1%	3.99 [0.91, 7.06]	_ <b></b>
Petrides 2015	32.78	9.24	15	24.4	8.3	16	8.0%	0.93 [0.18, 1.68]	+
Shiu1,2021	39.8	5.7	4	38.3	6	4	7.0%	0.22 [-1.17, 1.62]	+
Shiu 2,2021	42.1	2.7	4	41.3	3.5	4	7.0%	0.22 [-1.17, 1.62]	+
Wongsupa 2017	11.36	3.56	3	6.68	1.38	3	5.7%	1.39 [-0.70, 3.47]	
Zhu 2021 Subtotal (95% CI)	32.51	2.48	9 45	24.64	2.03	9 <b>46</b>	6.8% <b>46.1%</b>	3.31 [1.78, 4.84] 1.23 [0.38, 2.09]	
Heterogeneity: Tau <sup>2</sup>	= 0.73; Cł	hi² = 15.	15, df=	= 6 (P =	0.02); P	= 60%			
Test for overall effect	: Z = 2.83	(P = 0.)	005)						
4.1.4 12 weeks									
Collignon 2018	60.01		6	35.25		6	7.1%	1.46 [0.12, 2.80]	-
Liu 2011	35.92	2.53	6	22.86	0.55	6	3.7%	6.58 [3.18, 9.99]	
Yuan 2018 Subtotal (95% CI)	34.69	4.68	10 22	24.69	2.44	10 22	7.3% <b>18.1%</b>	2.57 [1.32, 3.81] <b>2.92 [0.95, 4.89]</b>	<b>→</b>
Heterogeneity: Tau <sup>2</sup> : Test for overall effect				2 (P = 0	1.02); I² =	= 74%			
4.1.5 10 weeks									
Colorado 2022 Subtotal (95% CI)	5.14	0.13	5 5	4.98	0.16	5 5	7.1% <b>7.1%</b>	0.99 [-0.37, 2.35] 0.99 [-0.37, 2.35]	
Heterogeneity: Not a Test for overall effect			15)						
4.1.6 17 weeks									
Campos 2018 Subtotal (95% Cl)	77.5	3.2	36 <b>36</b>	67.9	3.9	12 <b>12</b>	7.9% <b>7.9%</b>	2.79 [1.92, 3.67] <b>2.79 [1.92, 3.67]</b>	←
Heterogeneity: Not a Test for overall effect			00001)						
Total (95% CI)			151			128	100.0%	2.32 [1.45, 3.20]	•
Heterogeneity: Tau <sup>2</sup> : Test for overall effect					< 0.000	01); I²=	84%		-20 -10 0 10 20
Test for subgroup di		•			P = 0.06	), I² = 5	3.5%		Control Test

Figure 9. Forest plot for new bone area measures stratified by final follow-up

		Test		C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Annibali 2014	17.67	2.5	5	16.21	9.74	5	6.3%	1.46 [-7.35, 10.27]	+-
Cao 2015	56	3.6	4	0.47	2.19	4	7.3%	55.53 [51.40, 59.66]	+
Chamieh 2016	9.86	1.92	15	3.07	0.52	15	7.6%	6.79 [5.78, 7.80]	•
Chan 2022	39.81	3.16	6	41.32	3.57	6	7.4%	-1.51 [-5.32, 2.30]	-+
Jin 2019	26.03	3.53	5	8.95	3.25	5	7.3%	17.08 [12.87, 21.29]	-
Lee YC 2019	48.3	3	12	43.5	0.9	12	7.6%	4.80 [3.03, 6.57]	•
Lin 2019	47.61	7.08	10	30.08	2.13	10	7.2%	17.53 [12.95, 22.11]	-
Maillard 2022	11.67	2.85	10	4.84	2.33	10	7.5%	6.83 [4.55, 9.11]	+
Park 2022	3.62	1.94	4	6.47	4.07	4	7.3%	-2.85 [-7.27, 1.57]	
Shiu1,2021	41	1.4	4	38.4	1.3	4	7.6%	2.60 [0.73, 4.47]	•
Shiu 2,2021	41.2	3.4	4	39	5.1	4	6.9%	2.20 [-3.81, 8.21]	+
Vater 2022	29.45	19.5	12	28.28	12.8	11	5.0%	1.17 [-12.21, 14.55]	_ <b>_</b>
Wongsupa 2017	25.33	0.61	3	13.28	2.46	3	7.5%	12.05 [9.18, 14.92]	+
Zhu 2021	55.86	3.31	9	47.56	2.33	9	7.5%	8.30 [5.66, 10.94]	+
Total (95% CI)			103			102	100.0%	9.67 [4.52, 14.82]	◆
Heterogeneity: Tau <sup>2</sup>	= 90.07: (	Chi²=	653.67	. df = 13	(P < 0	.00001	l); <b>I<sup>2</sup> = 9</b> 89	%	
Test for overall effec								-	-100 -50 Ó 50 100
			,						Control Test

Figure 10. Forest plot for new bone volume measures




Figure 11. Funnel plot for new bone volume measures

		Test		C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
7.1.1 Rats									
Chamieh 2016	9.86	1.92	15	3.07	0.52	15	7.6%	6.79 [5.78, 7.80]	•
Jin 2019	26.03	3.53	5	8.95	3.25	5	7.3%	17.08 [12.87, 21.29]	-
Lin 2019	47.61	7.08	10	30.08	2.13	10	7.2%	17.53 [12.95, 22.11]	-
Subtotal (95% CI)			30			30	22.1%	13.59 [5.25, 21.93]	•
Heterogeneity: Tau <sup>2</sup> =				df = 2 (F	° < 0.0	0001); I	²=95%		
Test for overall effect:	Z = 3.19	9 (P = 1	0.001)						
7.1.2 Rabbits									
Chan 2022	39.81	3.16	6	41.32	3.57	6	7.4%	-1.51 [-5.32, 2.30]	-
Lee YC 2019	48.3	3	12	43.5	0.9	12	7.6%	4.80 [3.03, 6.57]	•
Shiu1,2021	41	1.4	4	38.4	1.3	4	7.6%	2.60 [0.73, 4.47]	+
Shiu 2,2021	41.2	3.4	4	39	5.1	4	6.9%	2.20 [-3.81, 8.21]	+
Wongsupa 2017	25.33	0.61	3	13.28	2.46	3	7.5%	12.05 [9.18, 14.92]	-
Subtotal (95% CI)			29			29	36.9%	4.22 [0.33, 8.10]	◆
Heterogeneity: Tau <sup>2</sup> =	: 16.66; (	Chi <b></b> ⁼=	40.79,	df = 4 (F	° < 0.0	0001); I	²=90%		
Test for overall effect	Z = 2.13	8 (P = 0	0.03)						
7.1.3 Mice									
Annibali 2014	17.67	2.5	5	16.21	9.74	5	6.3%	1.46 [-7.35, 10.27]	+
Maillard 2022	11.67	2.85	10	4.84	2.33	10	7.5%	6.83 [4.55, 9.11]	+
Park 2022	3.62	1.94	4	6.47	4.07	4	7.3%	-2.85 [-7.27, 1.57]	
Vater 2022	29.45	19.5	12	28.28	12.8	11	5.0%	1.17 [-12.21, 14.55]	
Zhu 2021	55.86	3.31	9	47.56	2.33	9	7.5%	8.30 [5.66, 10.94]	. <b>+</b>
Subtotal (95% CI)			40			39	33.6%	3.81 [-0.59, 8.20]	•
Heterogeneity: Tau <sup>2</sup> =				df = 4 (F	P = 0.0	004); I²	= 80%		
Test for overall effect:	Z=1.70	)(P=)	J.U9)						
7.1.4 Pigs									
Cao 2015	56	3.6	4	0.47	2.19	4	7.3%	55.53 [51.40, 59.66]	
Subtotal (95% Cl)			4			4	7.3%	55.53 [51.40, 59.66]	◆
Heterogeneity: Not ap	oplicable	9							
Test for overall effect	Z = 26.3	36 (P ≤	0.000	01)					
Total (95% CI)			103			102	100.0%	9.67 [4.52, 14.82]	◆
Heterogeneity: Tau <sup>2</sup> =	= 90.07: (	Chi²=	653.67	. df = 13	(P < 0	).00001	); <b> ²</b> = 989		
Test for overall effect:				•					-100 -50 0 50 10
Test for subgroup dif					3 (P < 1	0.0000	1), I² = 99	.3%	Control Test

Figure 12. Forest plot for new bone volume measures stratified by animal type





Figure 13. Forest plot for new bone volume measures stratified by defect type

		Test			ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
9.1.1 2 weeks									
Lin 2019 Subtotal (95% CI)	47.61	7.08	10 <b>10</b>	30.08	2.13	10 <b>10</b>	7.2% <b>7.2</b> %	17.53 [12.95, 22.11] 17.53 [12.95, 22.11]	•
Heterogeneity: Not ap	pplicable								
Test for overall effect	: Z = 7.50	) (P < (	0.0000	1)					
9.1.2 5 weeks									
Chamieh 2016 Subtotal (95% Cl)	9.86	1.92	15 15	3.07	0.52	15 15	7.6% <b>7.6</b> %	6.79 [5.78, 7.80] 6.79 [5.78, 7.80]	1
Heterogeneity: Not a	oplicable								·
Test for overall effect			0.0000	01)					
9.1.3 6 weeks									
Jin 2019	26.03		5		3.25	5	7.3%	17.08 [12.87, 21.29]	-
Lee YC 2019	48.3	3	12	43.5	0.9	12	7.6%	4.80 [3.03, 6.57]	[*
Vater 2022 Subtotal (95% CI)	29.45	19.5	12 29	28.28	12.8	11 28	5.0% <b>19.9</b> %	1.17 [-12.21, 14.55] 8.53 [-1.46, 18.53]	
Heterogeneity: Tau <sup>2</sup> =	- 66 10-7	≏hi≅ –		df = 27E	. ~ 0.0			0.55[-1.40, 10.55]	•
Test for overall effect				ui – 2 (r	~ 0.0	5001),1	- 33 %		
	. 2 - 1.01	ų – v	,						
9.1.4 8 weeks									
Annibali 2014	17.67	2.5	5	16.21	9.74	5	6.3%	1.46 [-7.35, 10.27]	+-
Chan 2022	39.81	3.16	6	41.32	3.57	6	7.4%	-1.51 [-5.32, 2.30]	-
Maillard 2022	11.67		10		2.33	10	7.5%	6.83 [4.55, 9.11]	+
Park 2022		1.94	4		4.07	4	7.3%	-2.85 [-7.27, 1.57]	
Shiu1,2021	41	1.4	4	38.4	1.3	4	7.6%	2.60 [0.73, 4.47]	Ē
Shiu 2,2021	41.2	3.4	4	39	5.1	4	6.9%	2.20 [-3.81, 8.21]	<b>T</b> .
Wongsupa 2017	25.33		3	13.28		3 9	7.5%	12.05 [9.18, 14.92]	
Zhu 2021 Subtotal (95% CI)	55.86	3.31	45	47.56	2.33	45	7.5% 57.9%	8.30 [5.66, 10.94] 3.99 [0.56, 7.43]	•
Heterogeneity: Tau <sup>2</sup> =	= 20.06° (	Chi₹=		df = 7 (F	. < 0.01			5155 [0150, 1145]	•
Test for overall effect				u	0.0		00,0		
9.1.5 12 weeks									
Cao 2015	56	3.6	4	0.47	2.19	4		55.53 [51.40, 59.66]	
Subtotal (95% CI)			4			4	7.3%	55.53 [51.40, 59.66]	•
Heterogeneity: Not a									
Test for overall effect	: Z = 26.3	16 (P <	0.000	J1)					
Total (95% CI)			103			102	100.0%	9.67 [4.52, 14.82]	•
Heterogeneity: Tau <sup>2</sup> =	= 90 07 <sup>.</sup> (	Chi <del>r</del> =		df = 13	(P < 0				· · · · · · · · · · · · · · · · · · ·
Test for overall effect							,,, <u>,</u> ,,	-	-100 -50 0 50 100
							1), <b>I</b> ² = 99		Control Test

Figure 14. Forest plot for new bone volume measures stratified by the final follow-up





of bone regenerated by DPSCs. It also showed a 'large' effect size by DPSC on bone regeneration. However, more studies in the future will provide the possibility of meta-analysis with more power. Furthermore, to achieve the best method of transplanting DPSCs in bone tissue engineering, future studies should compare the effects of growth factors, types of biological scaffolds, and other factors affecting bone regeneration by DPSCs. Therefore, more preclinical and clinical studies should be conducted in this field to overcome the clinical challenges of tissue engineering by DPSCs.

#### **Author Contributions**

**Conceptualization:** Fariba Emadian Razavi, Mohsen Naseri, and Neda Moeenzade.

**Methodology:** Fariba Emadian Razavi, Mohsen Naseri, and Neda Moeenzade.

Validation: Fariba Emadian Razavi.

Formal analysis: Fariba Emadian Razavi, Fereshteh Osmani, and Neda Moeenzade.

**Investigation:** Fariba Emadian Razavi, Mohsen Naseri, and Neda Moeenzade.

**Data curation:** Fariba Emadian Razavi, Fereshteh Osmani, and Neda Moeenzade.

Writing-original draft preparation: Neda Moeenzade.

Writing—review and editing: Fariba Emadian Razavi, Mohsen Naseri, and Fereshteh Osmani.

Supervision: Fariba Emadian Razavi.

Project administration: Fariba Emadian Razavi.

Funding acquisition: Fariba Emadian Razavi.

## Funding

This study was supported by a grant [No: 456197] from Birjand University of Medical Sciences (BUMS), Birjand, Iran.

## **Ethics Approval**

Not applicable.

#### **Competing Interests**

There are no conflicts of interest.

#### References

- Al-Moraissi EA, Oginni FO, Mahyoub Holkom MA, Mohamed AAS, Al-Sharani HM. Tissue-engineered bone using mesenchymal stem cells versus conventional bone grafts in the regeneration of maxillary alveolar bone: a systematic review and meta-analysis. Int J Oral Maxillofac Implants. 2020;35(1):79–90. doi: 10.11607/jomi.7682.
- 2. Chrcanovic BR, Albrektsson T, Wennerberg A. Bone quality and quantity and dental implant failure: a systematic review and meta-analysis. Int J Prosthodont. 2017;30(3):219-37. doi: 10.11607/ijp.5142.
- Rocchietta I, Fontana F, Simion M. Clinical outcomes of vertical bone augmentation to enable dental implant placement: a systematic review. J Clin Periodontol. 2008;35(8 Suppl):203-15. doi: 10.1111/j.1600-051X.2008.01271.x.
- Shanbhag S, Suliman S, Pandis N, Stavropoulos A, Sanz M, Mustafa K. Cell therapy for orofacial bone regeneration: a systematic review and meta-analysis. J Clin Periodontol. 2019;46 Suppl 21:162-82. doi: 10.1111/jcpe.13049.
- Di Benedetto A, Brunetti G, Posa F, Ballini A, Grassi FR, Colaianni G, et al. Osteogenic differentiation of mesenchymal stem cells from dental bud: role of integrins and cadherins. Stem Cell Res. 2015;15(3):618-28. doi: 10.1016/j.scr.2015.09.011.
- 6. Morad G, Kheiri L, Khojasteh A. Dental pulp stem cells for

in vivo bone regeneration: a systematic review of literature. Arch Oral Biol. 2013;58(12):1818-27. doi: 10.1016/j. archoralbio.2013.08.011.

- Shanbhag S, Pandis N, Mustafa K, Nyengaard JR, Stavropoulos A. Bone tissue engineering in oral peri-implant defects in preclinical in vivo research: a systematic review and metaanalysis. J Tissue Eng Regen Med. 2018;12(1):e336-e49. doi: 10.1002/term.2412.
- Qu H, Fu H, Han Z, Sun Y. Biomaterials for bone tissue engineering scaffolds: a review. RSC Adv. 2019;9(45):26252-62. doi: 10.1039/c9ra05214c.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/ journal.pmed.1000097.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.
- Behnia A, Haghighat A, Talebi A, Nourbakhsh N, Heidari F. Transplantation of stem cells from human exfoliated deciduous teeth for bone regeneration in the dog mandibular defect. World J Stem Cells. 2014;6(4):505-10. doi: 10.4252/ wjsc.v6.i4.505.
- 12. de Mendonça Costa A, Bueno DF, Martins MT, Kerkis I, Kerkis A, Fanganiello RD, et al. Reconstruction of large cranial defects in nonimmunosuppressed experimental design with human dental pulp stem cells. J Craniofac Surg. 2008;19(1):204-10. doi: 10.1097/scs.0b013e31815c8a54.
- Qian J, Jiayuan W, Wenkai J, Peina W, Ansheng Z, Shukai S, et al. Basic fibroblastic growth factor affects the osteogenic differentiation of dental pulp stem cells in a treatmentdependent manner. Int Endod J. 2015;48(7):690-700. doi: 10.1111/iej.12368.
- Zhang W, Walboomers XF, van Osch GJ, van den Dolder J, Jansen JA. Hard tissue formation in a porous HA/TCP ceramic scaffold loaded with stromal cells derived from dental pulp and bone marrow. Tissue Eng Part A. 2008;14(2):285-94. doi: 10.1089/tea.2007.0146.
- Otaki S, Ueshima S, Shiraishi K, Sugiyama K, Hamada S, Yorimoto M, et al. Mesenchymal progenitor cells in adult human dental pulp and their ability to form bone when transplanted into immunocompromised mice. Cell Biol Int. 2007;31(10):1191-7. doi: 10.1016/j.cellbi.2007.04.001.
- Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A. 2003;100(10):5807-12. doi: 10.1073/pnas.0937635100.
- Abe S, Hamada K, Miura M, Yamaguchi S. Neural crest stem cell property of apical pulp cells derived from human developing tooth. Cell Biol Int. 2012;36(10):927-36. doi: 10.1042/cbi20110506.
- Bressan E, Ferroni L, Gardin C, Pinton P, Stellini E, Botticelli D, et al. Donor age-related biological properties of human dental pulp stem cells change in nanostructured scaffolds. PLoS One. 2012;7(11):e49146. doi: 10.1371/journal.pone.0049146.
- Abe S, Yamaguchi S, Watanabe A, Hamada K, Amagasa T. Hard tissue regeneration capacity of apical pulp derived cells (APDCs) from human tooth with immature apex. Biochem Biophys Res Commun. 2008;371(1):90-3. doi: 10.1016/j. bbrc.2008.04.016.
- Kim S, Song JS, Jeon M, Shin DM, Kim SO, Lee JH. Ectopic hard tissue formation by odonto/osteogenically in vitro differentiated human deciduous teeth pulp stem cells. Calcif Tissue Int. 2015;97(1):80-9. doi: 10.1007/s00223-015-9989-1.
- 21. Ji F, Pan J, Shen Z, Yang Z, Wang J, Bai X, et al. The circular RNA circRNA124534 promotes osteogenic differentiation of

human dental pulp stem cells through modulation of the miR- $496/\beta$ -catenin pathway. Front Cell Dev Biol. 2020;8:230. doi: 10.3389/fcell.2020.00230.

- 22. Xavier Acasigua GA, Bernardi L, Braghirolli DI, Filho MS, Pranke P, Medeiros Fossati AC. Nanofiber scaffolds support bone regeneration associated with pulp stem cells. Curr Stem Cell Res Ther. 2014;9(4):330-7. doi: 10.2174/1574888x0966 6140228123911.
- 23. Ghavimi MA, Bani Shahabadi A, Jarolmasjed S, Memar MY, Maleki Dizaj S, Sharifi S. Nanofibrous asymmetric collagen/curcumin membrane containing aspirin-loaded PLGA nanoparticles for guided bone regeneration. Sci Rep. 2020;10(1):18200. doi: 10.1038/s41598-020-75454-2.
- d'Aquino R, Graziano A, Sampaolesi M, Laino G, Pirozzi G, De Rosa A, et al. Human postnatal dental pulp cells codifferentiate into osteoblasts and endotheliocytes: a pivotal synergy leading to adult bone tissue formation. Cell Death Differ. 2007;14(6):1162-71. doi: 10.1038/sj.cdd.4402121.
- Morito A, Kida Y, Suzuki K, Inoue K, Kuroda N, Gomi K, et al. Effects of basic fibroblast growth factor on the development of the stem cell properties of human dental pulp cells. Arch Histol Cytol. 2009;72(1):51-64. doi: 10.1679/aohc.72.51.
- Prabha RD, Kraft DCE, Harkness L, Melsen B, Varma H, Nair PD, et al. Bioactive nano-fibrous scaffold for vascularized craniofacial bone regeneration. J Tissue Eng Regen Med. 2018;12(3):e1537-e48. doi: 10.1002/term.2579.
- 27. Feitosa ML, Fadel L, Beltrão-Braga PC, Wenceslau CV, Kerkis I, Kerkis A, et al. Successful transplant of mesenchymal stem cells in induced osteonecrosis of the ovine femoral head: preliminary results. Acta Cir Bras. 2010;25(5):416-22. doi: 10.1590/s0102-86502010000500006.
- Laino G, d'Aquino R, Graziano A, Lanza V, Carinci F, Naro F, et al. A new population of human adult dental pulp stem cells: a useful source of living autologous fibrous bone tissue (LAB). J Bone Miner Res. 2005;20(8):1394-402. doi: 10.1359/jbmr.050325.
- Papaccio G, Graziano A, d'Aquino R, Graziano MF, Pirozzi G, Menditti D, et al. Long-term cryopreservation of dental pulp stem cells (SBP-DPSCs) and their differentiated osteoblasts: a cell source for tissue repair. J Cell Physiol. 2006;208(2):319-25. doi: 10.1002/jcp.20667.
- Laino G, Carinci F, Graziano A, d'Aquino R, Lanza V, De Rosa A, et al. In vitro bone production using stem cells derived from human dental pulp. J Craniofac Surg. 2006;17(3):511-5. doi: 10.1097/00001665-200605000-00021.
- 31. Ge X, Li Z, Zhou Z, Xia Y, Bian M, Yu J. Circular RNA SIPA1L1 promotes osteogenesis via regulating the miR-617/Smad3 axis in dental pulp stem cells. Stem Cell Res Ther. 2020;11(1):364. doi: 10.1186/s13287-020-01877-3.
- Niu LN, Sun JQ, Li QH, Jiao K, Shen LJ, Wu D, et al. Intrafibrillarsilicified collagen scaffolds enhance the osteogenic capacity of human dental pulp stem cells. J Dent. 2014;42(7):839-49. doi: 10.1016/j.jdent.2014.03.016.
- Mohanram Y, Zhang J, Tsiridis E, Yang XB. Comparing bone tissue engineering efficacy of HDPSCs, HBMSCs on 3D biomimetic ABM-P-15 scaffolds in vitro and in vivo. Cytotechnology. 2020;72(5):715-30. doi: 10.1007/s10616-020-00414-7.
- 34. Huang K, Wu J, Gu Z. Black phosphorus hydrogel scaffolds enhance bone regeneration via a sustained supply of calciumfree phosphorus. ACS Appl Mater Interfaces. 2019;11(3):2908-16. doi: 10.1021/acsami.8b21179.
- Fu Q, Ren H, Zheng C, Zhuang C, Wu T, Qin J, et al. Improved osteogenic differentiation of human dental pulp stem cells in a layer-by-layer-modified gelatin scaffold. J Biomater Appl. 2018;33(4):477-87. doi: 10.1177/0885328218799162.
- 36. Li JH, Liu DY, Zhang FM, Wang F, Zhang WK, Zhang ZT. Human dental pulp stem cell is a promising autologous

seed cell for bone tissue engineering. Chin Med J (Engl). 2011;124(23):4022-8. doi: 10.3760/cma.j.is sn.0366-6999.2011.23.033.

- 37. Riccio M, Maraldi T, Pisciotta A, La Sala GB, Ferrari A, Bruzzesi G, et al. Fibroin scaffold repairs critical-size bone defects in vivo supported by human amniotic fluid and dental pulp stem cells. Tissue Eng Part A. 2012;18(9-10):1006-13. doi: 10.1089/ten.TEA.2011.0542.
- Aimetti M, Ferrarotti F, Gamba MN, Giraudi M, Romano F. Regenerative treatment of periodontal intrabony defects using autologous dental pulp stem cells: a 1-year follow-up case series. Int J Periodontics Restorative Dent. 2018;38(1):51-8. doi: 10.11607/prd.3425.
- Monti M, Graziano A, Rizzo S, Perotti C, Del Fante C, d'Aquino R, et al. In vitro and in vivo differentiation of progenitor stem cells obtained after mechanical digestion of human dental pulp. J Cell Physiol. 2017;232(3):548-55. doi: 10.1002/jcp.25452.
- 40. Hernández-Monjaraz B, Santiago-Osorio E, Ledesma-Martínez E, Alcauter-Zavala A, Mendoza-Núñez VM. Retrieval of a periodontally compromised tooth by allogeneic grafting of mesenchymal stem cells from dental pulp: a case report. J Int Med Res. 2018;46(7):2983-93. doi: 10.1177/0300060518773244.
- 41. Li Y, Nan X, Zhong TY, Li T, Li A. Treatment of periodontal bone defects with stem cells from inflammatory dental pulp tissues in miniature swine. Tissue Eng Regen Med. 2019;16(2):191-200. doi: 10.1007/s13770-018-00175-7.
- 42. Rezaee M, Kazemi Oskuee R, Nassirli H, Malaekeh-Nikouei B. Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems. J Control Release. 2016;236:1-14. doi: 10.1016/j.jconrel.2016.06.023.
- 43. Ferrarotti F, Romano F, Gamba MN, Quirico A, Giraudi M, Audagna M, et al. Human intrabony defect regeneration with micrografts containing dental pulp stem cells: a randomized controlled clinical trial. J Clin Periodontol. 2018;45(7):841-50. doi: 10.1111/jcpe.12931.
- 44. Soares IMV, de Oliveira Fernandes GV, Larissa Cordeiro C, de Carvalho Leite YK, de Oliveira Bezerra D, de Carvalho MAM, et al. The influence of Aloe vera with mesenchymal stem cells from dental pulp on bone regeneration: characterization and treatment of non-critical defects of the tibia in rats. J Appl Oral Sci. 2019;27:e20180103. doi: 10.1590/1678-7757-2018-0103.
- 45. Huo JF, Zhang ML, Wang XX, Zou DH. Chrysin induces osteogenic differentiation of human dental pulp stem cells. Exp Cell Res. 2021;400(2):112466. doi: 10.1016/j. yexcr.2020.112466.
- Johnson ZM, Yuan Y, Li X, Jashashvili T, Jamieson M, Urata M, et al. Mesenchymal stem cells and three-dimensional-osteoconductive scaffold regenerate calvarial bone in critical size defects in swine. Stem Cells Transl Med. 2021;10(8):1170-83. doi: 10.1002/sctm.20-0534.
- 47. Yamada Y, Ito K, Nakamura S, Ueda M, Nagasaka T. Promising cell-based therapy for bone regeneration using stem cells from deciduous teeth, dental pulp, and bone marrow. Cell Transplant. 2011;20(7):1003-13. doi: 10.3727/096368910x539128.
- 48. Ikeda H, Sumita Y, Ikeda M, Ikeda H, Okumura T, Sakai E, et al. Engineering bone formation from human dental pulpand periodontal ligament-derived cells. Ann Biomed Eng. 2011;39(1):26-34. doi: 10.1007/s10439-010-0115-2.
- 49. Novais A, Lesieur J, Sadoine J, Slimani L, Baroukh B, Saubaméa B, et al. Priming dental pulp stem cells from human exfoliated deciduous teeth with fibroblast growth factor-2 enhances mineralization within tissue-engineered constructs implanted in craniofacial bone defects. Stem Cells Transl Med. 2019;8(8):844-57. doi: 10.1002/sctm.18-0182.

- Seo BM, Sonoyama W, Yamaza T, Coppe C, Kikuiri T, Akiyama K, et al. SHED repair critical-size calvarial defects in mice. Oral Dis. 2008;14(5):428-34. doi: 10.1111/j.1601-0825.2007.01396.x.
- 51. Feng G, Zhang J, Feng X, Wu S, Huang D, Hu J, et al. Runx2 modified dental pulp stem cells (DPSCs) enhance new bone formation during rapid distraction osteogenesis (DO). Differentiation. 2016;92(4):195-203. doi: 10.1016/j. diff.2016.06.001.
- 52. Wang W, Yuan C, Geng T, Liu Y, Zhu S, Zhang C, et al. EphrinB2 overexpression enhances osteogenic differentiation of dental pulp stem cells partially through ephrinB2-mediated reverse signaling. Stem Cell Res Ther. 2020;11(1):40. doi: 10.1186/s13287-019-1540-2.
- Collignon AM, Castillo-Dali G, Gomez E, Guilbert T, Lesieur J, Nicoletti A, et al. Mouse Wnt1-CRE-Rosa(tomato) dental pulp stem cells directly contribute to the calvarial bone regeneration process. Stem Cells. 2019;37(5):701-11. doi: 10.1002/stem.2973.
- 54. Xia Y, Chen H, Zhao Y, Zhang F, Li X, Wang L, et al. Novel magnetic calcium phosphate-stem cell construct with magnetic field enhances osteogenic differentiation and bone tissue engineering. Mater Sci Eng C Mater Biol Appl. 2019;98:30-41. doi: 10.1016/j.msec.2018.12.120.
- 55. Yang X, van der Kraan PM, Bian Z, Fan M, Walboomers XF, Jansen JA. Mineralized tissue formation by BMP2-transfected pulp stem cells. J Dent Res. 2009;88(11):1020-5. doi: 10.1177/0022034509346258.
- Jang JY, Park SH, Park JH, Lee BK, Yun JH, Lee B, et al. In vivo osteogenic differentiation of human dental pulp stem cells embedded in an injectable in vivo-forming hydrogel. Macromol Biosci. 2016;16(8):1158-69. doi: 10.1002/ mabi.201600001.
- 57. Imanishi Y, Hata M, Matsukawa R, Aoyagi A, Omi M, Mizutani M, et al. Efficacy of extracellular vesicles from dental pulp stem cells for bone regeneration in rat calvarial bone defects. Inflamm Regen. 2021;41(1):12. doi: 10.1186/s41232-021-00163-w.
- 58. Huang KH, Wang CY, Chen CY, Hsu TT, Lin CP. Incorporation of calcium sulfate dihydrate into a mesoporous calcium silicate/poly-ε-caprolactone scaffold to regulate the release of bone morphogenetic protein-2 and accelerate bone regeneration. Biomedicines. 2021;9(2):128. doi: 10.3390/ biomedicines9020128.
- 59. Ma L, Yu Y, Liu H, Sun W, Lin Z, Liu C, et al. Berberinereleasing electrospun scaffold induces osteogenic differentiation of DPSCs and accelerates bone repair. Sci Rep. 2021;11(1):1027. doi: 10.1038/s41598-020-79734-9.
- Serrano-Bello J, Cruz-Maya I, Suaste-Olmos F, González-Alva P, Altobelli R, Ambrosio L, et al. In vivo regeneration of mineralized bone tissue in anisotropic biomimetic sponges. Front Bioeng Biotechnol. 2020;8:587. doi: 10.3389/ fbioe.2020.00587.
- Covarrubias C, Cádiz M, Maureira M, Celhay I, Cuadra F, von Marttens A. Bionanocomposite scaffolds based on chitosangelatin and nanodimensional bioactive glass particles: in vitro properties and in vivo bone regeneration. J Biomater Appl. 2018;32(9):1155-63. doi: 10.1177/0885328218759042.
- 62. Hilkens P, Bronckaers A, Ratajczak J, Gervois P, Wolfs E, Lambrichts I. The angiogenic potential of DPSCs and SCAPs in an in vivo model of dental pulp regeneration. Stem Cells Int. 2017;2017:2582080. doi: 10.1155/2017/2582080.
- 63. Dubey N, Ferreira JA, Malda J, Bhaduri SB, Bottino MC. Extracellular matrix/amorphous magnesium phosphate bioink for 3D bioprinting of craniomaxillofacial bone tissue. ACS Appl Mater Interfaces. 2020;12(21):23752-63. doi: 10.1021/ acsami.0c05311.
- 64. Hu J, Cao Y, Xie Y, Wang H, Fan Z, Wang J, et al. Periodontal

regeneration in swine after cell injection and cell sheet transplantation of human dental pulp stem cells following good manufacturing practice. Stem Cell Res Ther. 2016;7(1):130. doi: 10.1186/s13287-016-0362-8.

- 65. Colorado C, Escobar LM, Lafaurie GI, Durán C, Perdomo-Lara SJ. Human recombinant cementum protein 1, dental pulp stem cells, and PLGA/hydroxyapatite scaffold as substitute biomaterial in critical size osseous defect repair in vivo. Arch Oral Biol. 2022;137:105392. doi: 10.1016/j. archoralbio.2022.105392.
- 66. Lee YC, Chan YH, Hsieh SC, Lew WZ, Feng SW. Comparing the osteogenic potentials and bone regeneration capacities of bone marrow and dental pulp mesenchymal stem cells in a rabbit calvarial bone defect model. Int J Mol Sci. 2019;20(20):5015. doi: 10.3390/ijms20205015.
- Jin Q, Yuan K, Lin W, Niu C, Ma R, Huang Z. Comparative characterization of mesenchymal stem cells from human dental pulp and adipose tissue for bone regeneration potential. Artif Cells Nanomed Biotechnol. 2019;47(1):1577-84. doi: 10.1080/21691401.2019.1594861.
- 68. Çolpak HA, Gönen ZB, Özdamar S, Alkan A, Kütük N. Vertical ridge augmentation using guided bone regeneration procedure and dental pulp derived mesenchymal stem cells with simultaneous dental implant placement: a histologic study in a sheep model. J Stomatol Oral Maxillofac Surg. 2019;120(3):216-23. doi: 10.1016/j.jormas.2018.12.011.
- 69. Lin CY, Kuo PJ, Chin YT, Weng IT, Lee HW, Huang HM, et al. Dental pulp stem cell transplantation with 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside accelerates alveolar bone regeneration in rats. J Endod. 2019;45(4):435-41. doi: 10.1016/j.joen.2018.12.019.
- Campos JM, Sousa AC, Caseiro AR, Pedrosa SS, Pinto PO, Branquinho MV, et al. Dental pulp stem cells and Bonelike® for bone regeneration in ovine model. Regen Biomater. 2019;6(1):49-59. doi: 10.1093/rb/rby025.
- Yuan M, Zhan Y, Hu W, Li Y, Xie X, Miao N, et al. Aspirin promotes osteogenic differentiation of human dental pulp stem cells. Int J Mol Med. 2018;42(4):1967-76. doi: 10.3892/ ijmm.2018.3801.
- 72. Wongsupa N, Nuntanaranont T, Kamolmattayakul S, Thuaksuban N. Assessment of bone regeneration of a tissueengineered bone complex using human dental pulp stem cells/ poly(ε-caprolactone)-biphasic calcium phosphate scaffold constructs in rabbit calvarial defects. J Mater Sci Mater Med. 2017;28(5):77. doi: 10.1007/s10856-017-5883-x.
- 73. Kuo TF, Lee SY, Wu HD, Poma M, Wu YW, Yang JC. An in vivo swine study for xeno-grafts of calcium sulfate-based bone grafts with human dental pulp stem cells (hDPSCs). Mater Sci Eng C Mater Biol Appl. 2015;50:19-23. doi: 10.1016/j. msec.2015.01.092.
- 74. Petridis X, Diamanti E, Trigas G, Kalyvas D, Kitraki E. Bone regeneration in critical-size calvarial defects using human dental pulp cells in an extracellular matrix-based scaffold. J Craniomaxillofac Surg. 2015;43(4):483-90. doi: 10.1016/j. jcms.2015.02.003.
- 75. Annibali S, Bellavia D, Ottolenghi L, Cicconetti A, Cristalli MP, Quaranta R, et al. Micro-CT and PET analysis of bone regeneration induced by biodegradable scaffolds as carriers for dental pulp stem cells in a rat model of calvarial "critical size" defect: preliminary data. J Biomed Mater Res B Appl Biomater. 2014;102(4):815-25. doi: 10.1002/jbm.b.33064.
- 76. Maraldi T, Riccio M, Pisciotta A, Zavatti M, Carnevale G, Beretti F, et al. Human amniotic fluid-derived and dental pulp-derived stem cells seeded into collagen scaffold repair critical-size bone defects promoting vascularization. Stem Cell Res Ther. 2013;4(3):53. doi: 10.1186/scrt203.
- 77. Chan YH, Ho KN, Lee YC, Chou MJ, Lew WZ, Huang HM, et al. Melatonin enhances osteogenic differentiation of dental

pulp mesenchymal stem cells by regulating MAPK pathways and promotes the efficiency of bone regeneration in calvarial bone defects. Stem Cell Res Ther. 2022;13(1):73. doi: 10.1186/s13287-022-02744-z.

- Liu HC, ELL, Wang DS, Su F, Wu X, Shi ZP, et al. Reconstruction of alveolar bone defects using bone morphogenetic protein 2 mediated rabbit dental pulp stem cells seeded on nanohydroxyapatite/collagen/poly(L-lactide). Tissue Eng Part A. 2011;17(19-20):2417-33. doi: 10.1089/ten.TEA.2010.0620.
- 79. Pisciotta A, Riccio M, Carnevale G, Beretti F, Gibellini L, Maraldi T, et al. Human serum promotes osteogenic differentiation of human dental pulp stem cells in vitro and in vivo. PLoS One. 2012;7(11):e50542. doi: 10.1371/journal. pone.0050542.
- Vater C, Männel C, Bolte J, Tian X, Goodman SB, Zwingenberger S. Effectiveness of dental pulp-derived stem cells and bone marrowderived mesenchymal stromal cells implanted into a murine critical bone defect. Curr Stem Cell Res Ther. 2022;17(5):480-91. doi: 10.2174/1574888x17666 220215100732.
- Maillard S, Sicard L, Andrique C, Torrens C, Lesieur J, Baroukh B, et al. Combining sclerostin neutralization with tissue engineering: an improved strategy for craniofacial bone repair. Acta Biomater. 2022;140:178-89. doi: 10.1016/j. actbio.2021.11.046.
- 82. Shiu ST, Lee WF, Chen SM, Hao LT, Hung YT, Lai PC, et al. Effect of different bone grafting materials and mesenchymal stem cells on bone regeneration: a micro-computed tomography and histomorphometric study in a rabbit calvarial defect model. Int J Mol Sci. 2021;22(15):8101. doi: 10.3390/ ijms22158101.
- Park H, Collignon AM, Lepry WC, Ramirez-GarciaLuna JL, Rosenzweig DH, Chaussain C, et al. Acellular dense collagen-S53P4 bioactive glass hybrid gel scaffolds form more bone than stem cell delivered constructs. Mater Sci Eng C Mater Biol Appl. 2021;120:111743. doi: 10.1016/j.msec.2020.111743.
- Collignon AM, Lesieur J, Anizan N, Azzouna RB, Poliard A, Gorin C, et al. Early angiogenesis detected by PET imaging with 64Cu-NODAGA-RGD is predictive of bone critical

defect repair. Acta Biomater. 2018;82:111-21. doi: 10.1016/j. actbio.2018.10.008.

- Chamieh F, Collignon AM, Coyac BR, Lesieur J, Ribes S, Sadoine J, et al. Accelerated craniofacial bone regeneration through dense collagen gel scaffolds seeded with dental pulp stem cells. Sci Rep. 2016;6:38814. doi: 10.1038/srep38814.
- Cao Y, Liu Z, Xie Y, Hu J, Wang H, Fan Z, et al. Adenovirusmediated transfer of hepatocyte growth factor gene to human dental pulp stem cells under good manufacturing practice improves their potential for periodontal regeneration in swine. Stem Cell Res Ther. 2015;6:249. doi: 10.1186/s13287-015-0244-5.
- Zhu Y, Wei SM, Yan KX, Gu YX, Lai HC, Qiao SC. Bovinederived xenografts immobilized with cryopreserved stem cells from human adipose and dental pulp tissues promote bone regeneration: a radiographic and histological study. Front Bioeng Biotechnol. 2021;9:646690. doi: 10.3389/ fbioe.2021.646690.
- Leyendecker Junior A, Gomes Pinheiro CC, Lazzaretti Fernandes T, Franco Bueno D. The use of human dental pulp stem cells for in vivo bone tissue engineering: a systematic review. J Tissue Eng. 2018;9:2041731417752766. doi: 10.1177/2041731417752766.
- Nakajima K, Kunimatsu R, Ando K, Ando T, Hayashi Y, Kihara T, et al. Comparison of the bone regeneration ability between stem cells from human exfoliated deciduous teeth, human dental pulp stem cells and human bone marrow mesenchymal stem cells. Biochem Biophys Res Commun. 2018;497(3):876-82. doi: 10.1016/j.bbrc.2018.02.156.
- 90. Li Y, Zhao S, Nan X, Wei H, Shi J, Li A, et al. Repair of human periodontal bone defects by autologous grafting stem cells derived from inflammatory dental pulp tissues. Stem Cell Res Ther. 2016;7(1):141. doi: 10.1186/s13287-016-0404-2.
- 91. d'Aquino R, De Rosa A, Lanza V, Tirino V, Laino L, Graziano A, et al. Human mandible bone defect repair by the grafting of dental pulp stem/progenitor cells and collagen sponge biocomplexes. Eur Cell Mater. 2009;18:75-83. doi: 10.22203/ ecm.v018a07.